Updates are available Correction dated 2023-02-04

Article History

Received: 29 September 2021

Accepted: 2 February 2022

First Online: 9 February 2022

Change Date: 4 February 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13195-023-01179-9

Declarations

:

: Informed consent was obtained from all subjects, and local institutional review boards for human research approved the study.

: All the co-authors have participated actively in this work and have read and agreed to this final version of the manuscript.

: I.I.G. reports no disclosures; V.M. reports no disclosures; S.B.E. reports no disclosures; M.L.M. reports no disclosures; N.F. reports no disclosures; A.E.W reports no disclosures; J.P. received an award from the Spanish Society of Neurology (best communication award); M.S.S reports no disclosures; A.B. was awarded in 2019 with the travel Fellowship from the Alzheimer’s Association to attend to the Alzheimer’s Association International Conference (AAIC); D.A. has a patent (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease) and participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., and Esteve Pharmaceuticals S.A; O.D.I reports no disclosures; O.B. has a patent (WO2019175379 A1 markers of synaptopathy in neurodegenerative disease); B.S.S. reports no disclosures; N.B. is member of the executive committee of the European Society of Radiology and reports examiner honoraria from the European Board of Neuroradiology; S.G.O. reports no disclosures; A. Llado reports no disclosures; R.B. reports honoraria from Nutricia; B.C.D reports no disclosures; H.J.R. reports honoraria from Biogen, Wave neuroscience, and Ionis; B.L.M. reports honoraria from Biogen, Cambridge University Press Guilford Publications, Inc. Oxford University Press Taylor & Francis Group Elsevier, Inc.; B.L.M. also served as medical/scientific advisor of The John Douglas French Foundation, The Larry L. Hillblom Foundation, Association for Frontotemporal Degeneration, National Institute for Health Research Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia, University of Washington ADRC, Stanford University ADRC, Arizona Alzheimer’s Disease Center (ADC), Massachusetts Alzheimer Disease Research Center, The Buck Institute for Research on Aging, University of Southern California (USC) PO1 Urban Air Pollution and Alzheimer’s Disease: Risk, Heterogeneity and Mechanisms. A.Lleó has a patent (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease); received personal consulting fees from Biogen, Nutricia, Roche, and Fujirebio-Europe; and has served at scientific advisory boards from Fujirebio-Europe, Nutricia, Biogen, and Roche Diagnostics and has filed a patent application of synaptic markers in neurodegenerative diseases; M.G.T. reports no disclosures; R.S.V. has served at scientific advisory boards from Wave pharmaceuticals and Ionis-Biogen and received personal honoraria from Janssen, Roche Diagnostics, Neuraxpharm for educational activities; D.C.P. reports no disclosures; J.F. has a patent (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease), has served at advisory boards for AC Immune, Zambon, and Lundbeck, and received honoraria for lectures from Roche, NovoNordisk, Esteve, and Biogen.